Elevated high-sensitivity C-reactive protein correlates with insulin resistance and hyper-E-selectinemia in patients with type 2 diabetes

Journal of the Japan Diabetes Society

Volumn 46, Issue 1, 2003, Pages 1-5

  Matsumoto, Kazunari ^a   Sera, Yasunori ^a   Abe, Yasuyo ^a   Tominaga, Tan ^a   Miyake, Seibei ^a  

^a SASEBO CHUO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CELL ACTIVATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037229593     PISSN: 0021437X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Ross R (1999) Atherosclerosis. An inflammatory disease. N Engl J Med 340: 115-126
2. Richardson M, Hadcock S, DeReske M, Cybulsky M (1994) Increased expression in vivo of VCAM-1 and E-selectin by the aortic endothelium of normolipemic and hyperlipemic diabetic rabbits. Arterioscler Thromb 14: 760-769
3. Endres M, Laufs U, Merz H, Kaps M (1997) Focal expression of intercellular adhesion molecule-1 in the human carotid bifurcation. Stroke 28: 77-82
4. DeGrava T (1997) Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque. Neurology 49: S15-S19
5. Ridker P, Cushman M, Stampfer M, Tracy R, Hennekens C (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973-979
6. Ridker P, Buring J, Shih J, Matias M, Hennekens C (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98: 731-733
7. Ridker P, Rifai N, Clearfield M, Downs J, Weis S, Miles J, Gotto A (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary event. N Engl J Med 344: 1959-1965
8. Matsumoto K, Miyake S, Yano M, Ueki Y, Yamaguchi Y, Akazawa S, Tominaga Y (1997) Insulin resistance and arteriosclerosis obliterans in patients with NIDDM. Diabetes Care 20: 1738-1743
9. Matsumoto K, Miyake S, Yano M, Ueki Y, Miyazaki A, Hirao K, Tominaga Y (1999) Insulin resistance and classic risk factors in type 2 diabetic patients with different subtypes of ischemic stroke. Diabetes Care 22: 1191-1195
10. Matsumoto K, Kizaki Y, Fukae S, Tomihira M, Sera Y, Ueki Y, Tominaga T, Miyake S (2001) Insulin resistance and coronary risk factors in Japanese type 2 diabetic patients with definite coronary artery disease. Diab Res Clin Pract 51: 181-186
11. Matsumoto K, Miyake S, Yano M, Ueki Y, Tominaga Y (2000) High serum concentrations of soluble E-selectin in patients with impaired glucose tolerance with hyperinsulinemia. Atherosclerosis 152: 415-420
12. Matsumoto K, Sera Y, Abe Y, Ueki Y, Miyake S (2001) Serum concentrations of soluble vascular cell adhesion molecule-1 and E-selectin are elevated in insulin-resistant patients with type 2 diabetes. Diabetes Care 24: 1697-1698
13. Matsumoto K, Sera Y, Miyake S, Ueki Y (2002) Serum levels of adhesion molecules correlate with insulin resistance. Atherosclerosis 161: 243-244
14. Matsumoto K, Sera Y, Nakamura H, Ueki Y, Miyake S (2002) Serum concentrations of soluble adhesion molecules are related to degree of hyperglycemia and insulin resistance in patients with type 2 diabetes mellitus. Diab Res Clin Pract 55: 131-138
15. Bonora E, Moghetti P, Zancanaro C, Cignoli M, Querena M, Cacciatori V, Corgnati A, Muggeo M (1989) Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic clamp studies. J Clin Endocrinol Metab 68: 674-378
16. Matsumoto K, Yano M, Miyake S, Ueki Y, Yamaguchi Y, Akazawa S, Tominaga Y (1998) Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care 21: 256-260
17. Rifai N, Tracy R, Ridker P (1999) Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 45: 2136-2141
18. Japanese source
19. Hak A, Stehouwer C, Bots M, Polderman K, Schalkwijk C, Westendorp I, Hofman A, Witteman J (1999) Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 19: 1986-1991
20. Tchernof A, Nolan A, Sites C, Ades P, Poehlman E (2002) Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 105: 564-569
21. Lemieux I, Pascot A, Prud'homme D, Almeras N, Bogaty P, Nadeau A, Bergeron J, Despres J (2001) Elevated C-reactive protein. Another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 20: 961-967
22. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy R, Haffner S (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome. Circulation 102: 42-47
23. Yudkin J, Stehouwer C, Emeis J, Coppack S (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol 19: 972-978
24. Carter A, Grant P (1997) Vascular homeostasis, adhesion molecules, and macrovascular disease in non-insulin-dependent diabetes mellitus. Diabet Med 14: 423-432
25. Ferri C, Desideri G, Baldoncini R, Bellini C, De Angelis C, Mazzocchi C, Santucci A (1998) Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities. Diabetes 47: 660-667
26. Caballero A, Arora S, Saouaf R, Lim S, Smakowski P, Park J, King G, LoGerfo F, Horton E, Veves A (1999) Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 48: 1856-1862
27. Japanese source
28. Cominacini L, Garbin U, Pasini A, Campagnola M, Davoli A, Foot E, Sighieri G, Sironi A, Lo Cascio V, Ferrannini E (1998) Troglitazone reduces LDL oxidation and lowers plasma E - selectin concentration in NIDDM patients. Diabetes 47: 130-133